← DeepTechTracker
Switchpoint Bio's five co-founders standing together indoors, as identified in the company's funding announcement.

Switchpoint Bio raises $5.3 million to track treatment response through blood

Photo: Switchpoint Bio, official funding announcement. Its five co-founders, from left: Jussi Paananen, Niilo Färkkilä, Samuel Myllykangas, Mitja Kurki and Jason Buenrostro.

Switchpoint Bio has raised $5.3 million in pre-seed financing to develop a blood-based way to follow how disease and treatment change a patient's biology. The November 10 announcement includes a $5 million investment from Treehouse Delmar Investments. That investment is part of the total, not an additional round; the company does not identify every contributor to the remaining financing.

The Helsinki- and Cambridge, Massachusetts-based company studies DNA methylation: chemical tags on DNA that help regulate how a cell uses its genes. Those tags can change with disease, exposures and treatment. Switchpoint focuses its blood assay on selected regions relevant to disease and the immune system, rather than trying to read every possible mark. Its aim is to give drug developers a repeatable view of what changes after treatment and what persists.

The platform combines targeted methylation measurements with AI, reference data describing individual cells and population-scale datasets. In plain terms, the company wants to connect patterns measured in an ordinary blood sample to the underlying behaviour of immune cells. That could help researchers understand why some patients respond to a drug and others do not, but it remains a development and validation goal, not an established clinical outcome.

Switchpoint is testing its approach in autoimmune disease, including systemic lupus erythematosus, or SLE, in which the immune system attacks the body's own tissues. It wants to find out whether disease-related immune states can be identified from blood and tracked through treatment. The company says it is discussing its first industry validation programs with pharmaceutical and biotechnology companies; those discussions are not announced completed partnerships.

Co-founders Samuel Myllykangas and Jason Buenrostro previously collaborated on targeted sequencing technologies at Stanford. Myllykangas built Blueprint Genetics, acquired by Quest Diagnostics in 2020. Buenrostro is a Harvard professor and inventor of ATAC-seq, a method used to study which parts of DNA are accessible within cells. Fellow co-founders Niilo Färkkilä, Jussi Paananen and Mitja Kurki bring pharmaceutical, genomics and data-platform experience.

The financing will support clinical and industry validation, larger clinical and biobank datasets, development of the epigenomic and AI platform, and scientific and technical hiring. The company is moving from platform development into validation. The announcement does not establish a regulatory approval, a diagnostic product ready for routine clinical use or independently proven treatment-response prediction.

Read at source ↗

DTT summary based on Switchpoint Bio's report. The full article is on the publisher's site.

Additional reporting

Financing

$5.3 million pre-seed, announced November 10, 2026; includes $5 million from Treehouse Delmar Investments.

What it measures

Selected DNA methylation marks in blood, combined with AI and reference datasets to study disease biology and treatment response.

Validation

Testing in autoimmune disease, including SLE; first industry validation programs are being discussed, not announced as completed partnerships.

Use of funds

Validation, clinical and biobank datasets, platform development, and scientific and technical hiring.

Team

Samuel Myllykangas, Jason Buenrostro, Niilo Färkkilä, Jussi Paananen and Mitja Kurki; Helsinki and Cambridge, Massachusetts.

Browse more DeepTech news →

Who's raising. Who's funding. What's next in DeepTech.